what are the risks of glp 1 drugs Benefits and GLP-1 Receptor Agonists Outlined GLP-1 Drugs and Eating Disorders:
Description
Saxagliptin is not recommended in patients with ESRD, while alogliptin and sitagliptin can be used at doses of 6.25 mg and 25 mg respectively
10.1089/cap.2016.0046 308
This corresponds to a relative reduction of 17%
Key Findings 12.2
Obesity with Cardiovascular Disease 10.2.3
It affects portions, hunger, fullness, and metabolic signaling
